Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 7Thoracic 2Gastrointestinal 2Breast 2Head & Neck 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Glioblastoma 8Brain Neoplasms 5Neoplasms 4Glioma 3Medulloblastoma 2Breast Neoplasms 2Triple Negative Breast Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Ketosis 1Insulin Resistance 1Gliosarcoma 1Diabetes Mellitus 1Colonic Neoplasms 1Cognitive Dysfunction 1Chondrosarcoma 1Cholangiocarcinoma 1Astrocytoma 1

Interventions

Radiosurgery 22Nivolumab 21Ipilimumab 19pembrolizumab 15Temozolomide 11dabrafenib 10binimetinib 10encorafenib 8Cyclophosphamide 8trametinib 7Magnetic Resonance Spectroscopy 7Bevacizumab 6fludarabine 5cobimetinib 5Specimen Handling 5CTLA-4 Antigen 5fludarabine phosphate 3aldesleukin 3Vemurafenib 3Thalidomide 3Paclitaxel 3Oxaliplatin 3Interleukin-2 3Gemcitabine 3Drug Therapy 3Carboplatin 3130-nm albumin-bound paclitaxel 3ulixertinib 2tovorafenib 2relatlimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Metformin × CNS × Clear all
NCT04001725 2019-11-13

OPTIMAL

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Unknown
110 enrolled
BreastCNSDermatologicThoracic

Brain Neoplasms, Breast Neoplasms, Diabetes Mellitus, Lung Neoplasms, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡